Dr Reddy’s subsidiary gets positive outcome for CAR-T cell trial

9 Oct 2024 , 03:48 PM

Dr Reddys Laboratories‘ shares increased more than 1% to ₹6,755 in morning trading on October 9 after its subsidiary, Aurigene Oncology Limited, revealed excellent results from its first clinical study of Ribrecabtagene autoleucel (DRL-1801). This was a significant milestone in India’s use of CAR-T cell therapy to treat multiple myeloma, a kind of blood cancer.

At around closing hours, Dr Reddy’s was trading marginally higher at ₹6,660 per piece, against the previous close of ₹6,656.05 on NSE. The counter touched an intraday high and low of ₹6,754.90, and ₹6,647.10, respectively.

The experiment also had a favourable safety profile, with no serious adverse effects such as Cytokine Release Syndrome (CRS) or neurotoxicity reported. Based on Phase 1 results, the Drugs Controller General of India (DCGI) has cleared the start of Phase 2.

In the SWASTH research, all eight people reacted to the medication, with 62.50% having a full response. These patients had received an average of 5.5 previous therapies, which included transplants.

Murali Ramachandra, CEO of Aurigene Oncology, stated that the medicine has the potential to be transformative for Indian myeloma sufferers. Ribrecabtagene autoleucel, which is made in Aurigene’s Bangalore laboratory, combats cancer cells using a specific antibody and lentivirus. Aurigene, founded in 2002, specialises in cancer therapeutics and currently has ten medications in development.

For feedback and suggestions, write to us at [e-mail]